Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates

Core Viewpoint - Quest Diagnostics reported quarterly earnings of $2.21 per share, exceeding the Zacks Consensus Estimate of $2.15 per share, and showing an increase from $2.04 per share a year ago, indicating a positive earnings surprise of 2.79% [1] Financial Performance - The company achieved revenues of $2.65 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.46%, and up from $2.37 billion in the same quarter last year [2] - Over the last four quarters, Quest Diagnostics has consistently exceeded consensus EPS estimates and revenue expectations [2] Stock Performance - Quest Diagnostics shares have increased approximately 7.3% since the beginning of the year, contrasting with a decline of 12.3% in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.53 on revenues of $2.68 billion, and for the current fiscal year, it is $9.68 on revenues of $10.76 billion [7] - The trend of estimate revisions for Quest Diagnostics is mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Quest Diagnostics belongs, is currently ranked in the top 8% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]